Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

(2016) Dan Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice

(2016) Andrea N. Edginton et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy

(2016) L. Nie et al.   CLINICAL CANCER RESEARCH

Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults

(2016) Dianne Pulte et al.   INTERNATIONAL JOURNAL OF CANCER

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example

(2015) J. R. Sachs et al.   CLINICAL CANCER RESEARCH

Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma

(2015) Miki Shimada et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Signal Transduction in Cancer

(2015) R. Sever et al.   Cold Spring Harbor Perspectives in Medicine

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant

(2014) Sarah L. Sammons et al.   AMERICAN JOURNAL OF HEMATOLOGY

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

(2014) F Ravandi et al.   LEUKEMIA

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

(2013) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

(2012) B. C. Widemann et al.   CLINICAL CANCER RESEARCH

Incidence, survival and prevalence of myeloid malignancies in Europe

(2012) O. Visser et al.   EUROPEAN JOURNAL OF CANCER

Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis

(2012) P. Boudou-Rouquette et al.   ONCOLOGIST

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

(2011) Lokesh Jain et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Saturable absorption of sorafenib in patients with solid tumors: a population model

(2011) Marilyne Hornecker et al.   INVESTIGATIONAL NEW DRUGS

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

(2011) Maria Cristina Villarroel et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography–tandem mass spectrometry

(2010) Lie Li et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

(2010) Michael Crump et al.   LEUKEMIA & LYMPHOMA

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

(2009) M Gomberg-Maitland et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R

(2008) Emmanuelle Comets et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE